Eduardo Ruman (In Memoriam)
President-Director
Administrative And Entrepreneur
Denise Ruman
MTB - 0086489
JORNALISTA RESPONSÁVEL
The Biggest and Best International Newspaper for World Peace
Founder, President And International General Chief-Director :  Denise Ruman - MTB: 0086489 / SP-BRAZIL
Mentor of the Newspaper : José Cardoso Salvador (in memoriam)
Mentor-Director : Mahavátar Babají (in memoriam)

Saúde / 16/04/2021

COVID 19 NEWS

Drug that prevents worsening of Covid may be released by Anvisa

0 votes
Drug that prevents worsening of Covid may be released by Anvisa


Regen-Cov, the American company Regeneron, which offers 76% protection against the symptoms of the disease and reduces the risk of contamination by those who live with an infected by 81% may be released by Anvisa in the coming weeks.

Composed of two antibodies, the treatment costs 2 thousand dollars, about 11.5 thousand reais.

The product formed by the monoclonal antibodies casirivimab and imdevimab, produced in the laboratory, and applied in a single dose by means of an injection.

Prevents the worsening of cases

It has been shown to be effective in preventing the progression of Covid-19 and also preventing the spread of people living with someone infected.

This is what the results of two tests carried out by the manufacturer in partnership with NIAID (National Institute of Allergy and Infectious Diseases of the USA) indicate.

Tests

In the first, 204 people who had just been diagnosed with Covid-19, but were asymptomatic, were divided into two groups (control and placebo).

Among those who took the drug, there were 76% fewer cases of progression to symptomatic Covid, three days after the drug was administered.

Among patients who had symptoms, they lasted 45% less time - and there was a total reduction, of 100%, in cases of hospitalization for the disease.

The second test involved 1,505 volunteers, who had no coronavirus - but lived with people infected with Sars-CoV-2. They were divided into two groups: half received Regen-Cov and the other half a placebo.

In the group that took the medicine, there were 72% fewer cases of infection with Sars-CoV-2 one week after applying the drug. This protection grew to 93% in the following weeks, and stabilized at 81% after one month.

Side effects

1.6% of the volunteers had side effects, such as nausea, vomiting, fever, chills and intestinal obstruction - but this only happened when the drug was applied in high doses, of 2,400 mg or 8,000 mg.

The standard dose, which has been shown to be effective, is 1,200 mg.

FDA approval

Regen-Cov obtained emergency authorization the FDA in February 2021.

It is applied via subcutaneous injection, and costs $ 2,000 in the United States.

In Brazil, Anvisa has until May 1 to issue an opinion on emergency use. Remembering that the drug is a complement to the treatment and does not eliminate immunization by vaccines.


Comentários
0 comentários


  • Enviar Comentário
    Para Enviar Comentários é Necessário estar Logado.
    Clique Aqui para Entrar ou Clique Aqui para se Cadastrar.

Ainda não Foram Enviados Comentários!

Copyright 2021 - Jornal Pacifista - All rights reserved. powered by WEB4BUSINESS

Inglês Português Frances Italiano Alemão Espanhol Árabe Bengali Urdu Esperanto Croata Chinês Coreano Grego Hebraico Japonês Hungaro Latim Persa Polonês Romeno Vietnamita Swedish Thai Czech Hindi Você